Document is current

Article History

Received: 12 April 2023

Accepted: 18 March 2024

First Online: 29 March 2024

Declarations

:

: Experiments with mice were conducted in accordance with the guidelines of the Animal Care and Use Committee of Barcelona Science Park (protocol CEEA-PCB-14-000275). Healthy PBMC donors were collected with written informed consent at the Centro Nacional de Análisis Genómico (CNAG). Healthy human buffy coats were provided by the Australian Red Cross Blood Service, and the ethical approval was obtained by the Melbourne Human Ethics Committee (01/14). Colon biopsies from Ulcerative Colitis patients in remission were collected with written informed consent at the Hospital Clinic of Barcelona with ethical approval granted by the clinical research ethics committee of the Hospital Clínic of Barcelona (Reg. HCB/2022/0125). Prostate tissues were collected with written informed consent from previously untreated patients undergoing radical prostatectomy at St. Andrew’s Hospital, Adelaide, Australia, through the Australian Prostate Cancer BioResource. Ethical approval for tissue collection and experimentation was obtained from St Andrew’s (#80) and the University of Adelaide (H-2012-016) Human Research Ethics committees. This study was conducted in accordance with the Declaration of Helsinki principles.

: Not applicable.

: H.H. is a co-founder and shareholder of Omniscope, a scientific advisory board member of MiRXES and Nanostring, and a consultant to Moderna and Singularity. L.G.M is an advisor and shareholder of Omniscope and advisor for ArgenTAG, Millenium Sciences, and Truckee Applied Genomics. J.C.N. is a consultant of Omniscope. M.C.N. has received grants (unrestricted) from GSK, the European Commission, and Lung Foundation Netherlands. M.v.d.B. has received grants (unrestricted) from AstraZeneca, Novartis, GlaxoSmithKline, Roche, Genentech, and Sanofi. F.T. received speaker’s fees from Falk, Janssen, and AbbVie. S.S. has been a consultant for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Ferring, Genentech/Roche, Janssen, Lilly, Novartis, Merck Sharp Dohme, Medimmune/AstraZeneca, Pfizer, Protagonist, Sanofi, Takeda, Theravance, and UCB and is a paid speaker for AbbVie, Ferring, Janssen, Merck Sharp Dohme, Novartis, Takeda, and UCB. P.R. has been a consultant for Takeda and Omass. I.A.P. holds current research grants with AstraZeneca and BMS. Omniscope has filed a patent related to the application of the FixNCut protocol. All other authors declare no competing interests.